Vericiguat Medicine 04 December 2025 Extended indication Extension of indication for treatment of symptomatic chronic Heart failure with reduced ejection fraction in adults and elderly who have not had a recent hospitalization for heart failure or need for outpatient intravenous diuretics. Therapeutic value Possibly no place in the treatment regimen Total cost Registration phase Clinical trials Product Active substance Vericiguat Domain Cardiovascular diseases Reason of inclusion Indication extension IND Main indication Other medication for cardiovascular diseases Extended indication Extension of indication for treatment of symptomatic chronic Heart failure with reduced ejection fraction in adults and elderly who have not had a recent hospitalization for heart failure or need for outpatient intravenous diuretics. Current proprietary name Already available biosimilars / generics Proprietary name Verquvo Manufacturer Bayer Portfolio holder Bayer Mechanism of action Other Route of administration Oral Therapeutical formulation Tablet Budgetting framework Extramural (GVS) Centre of expertise Additional remarks Stimulator van het soluble guanylate cyclase (sGC) enzym. Registration Registration route Centralised (EMA) Type of trajectory Normal trajectory Particularity Unknown ATMP No Submission date 2025 Expected Registration 2026 Orphan drug No Registration phase Clinical trials Reimbursement Medicine sluice Additional remarks Therapeutic value Current treatment options Patienten met HFrEF ontvangen veel verschillende soorten medicatie via een Stappenplan hartfalen medicatie. Therapeutic value Possibly no place in the treatment regimen This assessment does not indicate any potential inclusion in the package. Substantiation De VICTOR-trial miste het primaire eindpunt en eerdere grote studies lieten geen significant effect zien. Een meta-analyse suggereert mogelijk voordeel in sommige subgroepen, maar het middel zal waarschijnlijk geen grote rol gaan spelen. Duration of treatment Frequency of administration 1 times a day Dosage per administration 2,5mg, 5mg of 10mg References NCT05093933 (VICTOR); Expertopinie Additional remarks Expected patient volume per year Patient volume Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Additional remarks In Nederland zijn er circa 240.000 patiënten met hartfalen. Jaarlijks diagnose in circa 38.000 patiënten. Hiervan is circa twee derde HFrEF. Een klein gedeelte van de patiënten zal mogelijk vericiguat ontvangen. Expected cost per patient per year Cost € < 1,193.00 This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year. References Z-index Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use No Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks